Oramed Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Oramed Pharmaceuticals

07/03/2024 03:17

* Oramed Pharmaceuticals Inc  ORMP.OQ  reported quarterly
adjusted
earnings of 33 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -22 cents.  The mean expectation of
two analysts for the quarter was for a loss of 12 cents per
share. Wall Street expected results to range from -23 cents
to -1 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Oramed Pharmaceuticals Inc's reported EPS for the quarter
was 33
cents​.
    * The company reported quarterly net income of $13.34
million.
    * Oramed Pharmaceuticals Inc shares had risen by 41.1% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 47.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Oramed
Pharmaceuticals Inc is $4.25 
This summary was machine generated from LSEG data March 7 at
03:17 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.12          0.33           Beat
 Sep. 30 2023      -0.08          -0.08          Met
 Jun. 30 2023      -0.10          -0.03          Beat
 Mar. 31 2023      -0.26          -0.08          Beat